News
07-01-2013, 01:30 AM
Some women treated for ER-positive breast cancer are at higher risk for recurrence after completing tamoxifen treatment. Now a new US study suggests that by measuring a genetic biomarker, it may be possible to predict which women will have this higher risk, thus sparing a lot of women from treatment they don't need...
More... (http://www.medicalnewstoday.com/articles/262713.php)
More... (http://www.medicalnewstoday.com/articles/262713.php)